You are here

Article Text

Article menu

other Versions

Download PDFPDF
Correspondence
Statins in systemic lupus erythematosus
  1. Carlos Abud-Mendoza
  1. Regional Unit of Rheumatology and Osteoporosis, Central Hospital ‘Dr. Ignacio Morones Prieto’ and Faculty of Medicine, Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico
  1. Correspondence to Dr Carlos Abud-Mendoza, Regional Unit of Rheumatology and Osteoporosis, Central Hospital ‘Dr. Ignacio Morones Prieto’ and Faculty of Medicine, Universidad Autónoma de San Luis Potosí, 78300 San Luis, S.L.P., Mexico; c_abud{at}hotmail.com

https://doi.org/10.1136/annrheumdis-2017-212463

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Statins represent an important therapeutic option for prescription by rheumatologists due to their preventive effects related to cardiovascular disease as well as their immunoregulatory activity.

    De Jong et al1 recently published a report emphasising the use of statins as safety drugs, whose diverse effects in immune modulation could be related to autoimmune disorders. Although De Jong’s cohort shows no association with autoimmune disease development such as systemic lupus erythematosus (SLE), in our view, the data could support potential prevention of SLE.

    Fasano et al2 recently …

    View Full Text

    Footnotes

    • Competing interests None declared.

    • Patient consent I would like comment some aspects of De Jong’s et al. paper.

    • Provenance and peer review Not commissioned; internally peer reviewed.